AstraZeneca Looks To Muscle In On BMS-Dominated Neoadjuvant NSCLC Setting
Without disclosing data, the company reported positive pathological complete response data from the AEGEAN study of its PD-L1 inhibitor Imfinzi in neoadjuvant NSCLC, where BMS’s Opdivo won approval in March.
You may also be interested in...
AstraZeneca Advances In Early Stage Lung Cancer With Imfinzi And Tagrisso
AstraZeneca’s Imfinzi is playing catch-up to other PD1/L1 targeting agents in neoadjuvant/adjuvant NSCLC with new data from AEGEAN, but new survival data for Tagrisso from ADAURA consolidate its dominance in early-stage EGFR positive disease.
AstraZeneca’s Susan Galbraith On What’s Next In The Cancer Pipeline
One of the architects of AstraZeneca’s burgeoning cancer portfolio, oncology R&D head Susan Galbraith is making sure the firm does not rest on its laurels. She talked to Scrip about what’s coming next from the UK major’s cancer pipeline.
Innate Lead Candidate Fails In Head And Neck Cancer But Partner AZ Offers Hope In NSCLC
Innate’s lead candidate has reached the end of the road in head and neck carcinoma after a disappointing interim Phase III trial analysis but hope remains that a combination with partner AstraZeneca's Imfinzi could succeed elsewhere.